This is a Phase III, randomized, open-label multicentre study that will evaluate the efficacy and safety of giredestrant compared with fulvestrant, both in combination with the investigator's choice of a CDK4/6 inhibitor (palbociclib, ribociclib or abemaciclib), in participants with ER-positive HER2-negative advanced breast cancer who have developed resistance to adjuvant endocrine therapy.
New Zealand trial sites will be Palmerston North and Northland.
Read more about this trial here.
29 April 2024
